ID25789A - KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B - Google Patents

KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B

Info

Publication number
ID25789A
ID25789A IDW20000522D ID20000522D ID25789A ID 25789 A ID25789 A ID 25789A ID W20000522 D IDW20000522 D ID W20000522D ID 20000522 D ID20000522 D ID 20000522D ID 25789 A ID25789 A ID 25789A
Authority
ID
Indonesia
Prior art keywords
pct
combination
alkyl
ht1b
antagonists
Prior art date
Application number
IDW20000522D
Other languages
English (en)
Indonesian (id)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ID25789A publication Critical patent/ID25789A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20000522D 1997-09-18 1998-09-09 KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B ID25789A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703376A SE9703376D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
ID25789A true ID25789A (id) 2000-11-02

Family

ID=20408296

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20000522D ID25789A (id) 1997-09-18 1998-09-09 KOMBINASI DARI INHIBITOR MONOAMINA OKSIDASI DAN ANTAGONIS ATAU SEBAGIAN AGONIS h5-HT1B

Country Status (27)

Country Link
US (1) US6159970A (cg-RX-API-DMAC10.html)
EP (1) EP1014986B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516719A (cg-RX-API-DMAC10.html)
KR (2) KR20010024087A (cg-RX-API-DMAC10.html)
CN (1) CN1278727A (cg-RX-API-DMAC10.html)
AR (1) AR013503A1 (cg-RX-API-DMAC10.html)
AT (1) ATE270889T1 (cg-RX-API-DMAC10.html)
AU (1) AU752719B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812236A (cg-RX-API-DMAC10.html)
CA (1) CA2302204A1 (cg-RX-API-DMAC10.html)
DE (1) DE69825062T2 (cg-RX-API-DMAC10.html)
DK (1) DK1014986T3 (cg-RX-API-DMAC10.html)
EE (1) EE200000146A (cg-RX-API-DMAC10.html)
ES (1) ES2222603T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0100621A2 (cg-RX-API-DMAC10.html)
ID (1) ID25789A (cg-RX-API-DMAC10.html)
IL (1) IL134775A0 (cg-RX-API-DMAC10.html)
IS (1) IS5401A (cg-RX-API-DMAC10.html)
MX (1) MXPA00002616A (cg-RX-API-DMAC10.html)
NO (1) NO20001400L (cg-RX-API-DMAC10.html)
PL (1) PL339368A1 (cg-RX-API-DMAC10.html)
PT (1) PT1014986E (cg-RX-API-DMAC10.html)
SE (1) SE9703376D0 (cg-RX-API-DMAC10.html)
SK (1) SK2832000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000725T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999013878A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987804B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957948A (en) * 1988-05-05 1990-09-18 Interface, Inc. Biocidal protective coating for heat exchanger coils
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
CN101448803A (zh) * 2006-03-17 2009-06-03 阿斯利康(瑞典)有限公司 用作5-ht6调节剂的四氢萘
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110179988A (zh) * 2019-07-10 2019-08-30 王大伟 五羟色胺再摄取抑制剂和单胺氧化酶抑制剂联合在制备治疗抑郁症或早泄药物中的应用
IL321485A (en) * 2022-12-14 2025-08-01 Luminous Mind Inc Treatment of psychological symptoms affecting other medical conditions (PFAOMC)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
KR20010024087A (ko) 2001-03-26
PL339368A1 (en) 2000-12-18
DK1014986T3 (da) 2004-10-25
US6159970A (en) 2000-12-12
CA2302204A1 (en) 1999-03-25
IS5401A (is) 2000-03-14
BR9812236A (pt) 2000-07-18
DE69825062D1 (de) 2004-08-19
PT1014986E (pt) 2004-10-29
CN1278727A (zh) 2001-01-03
ES2222603T3 (es) 2005-02-01
ATE270889T1 (de) 2004-07-15
WO1999013878A1 (en) 1999-03-25
EP1014986B1 (en) 2004-07-14
AU9193198A (en) 1999-04-05
NO20001400L (no) 2000-05-05
SE9703376D0 (sv) 1997-09-18
NO20001400D0 (no) 2000-03-17
AU752719B2 (en) 2002-09-26
JP2001516719A (ja) 2001-10-02
SK2832000A3 (en) 2000-09-12
ZA987804B (en) 1999-03-18
EE200000146A (et) 2001-02-15
AR013503A1 (es) 2000-12-27
TR200000725T2 (tr) 2000-08-21
KR20010024084A (ko) 2001-03-26
DE69825062T2 (de) 2005-08-25
EP1014986A1 (en) 2000-07-05
MXPA00002616A (es) 2002-04-24
HUP0100621A2 (hu) 2001-08-28
IL134775A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
SE9703375D0 (sv) A new combination
SE9703376D0 (sv) A new combination
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
DK526188A (da) Benzimidazolin-2-oxo-1-carboxylsyrederivater til anvendelse som 5-ht receptorantagonister i farmaceutiske praeparater
DK0771197T3 (da) Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR032466A1 (es) Ciclilamina sulfonamidas, utilizacion de las mismas para la manufactura de un medicamento y composiciones farmaceuticas utiles como agonistas de los receptores beta-3 adrenergicos
PE20011114A1 (es) Decahidro-isoquinolinas
PE20011212A1 (es) Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister
YU25696A (sh) Postupak dobijanja kombinacije (r)-5-karbamoil-8-fluoro-3- n,n-disupstituisan-amino-3,4-dihloro-2h-1-bezopirana i farmaceutske formulacije koje ih sadrže
PE20001234A1 (es) Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1
FI943931A0 (fi) Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina
SE9804126D0 (sv) New pharmaceutical composition
SE9703374D0 (sv) A new combination
FI945582A0 (fi) Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina
NO20041704L (no) Substituerte alkylaminopyridazinonderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder disse
FI940568A0 (fi) Anti-inflammatorisina aineina toimivia oksindoli-1-(N-(alkoksikarbonyyli))karboksamideja ja -1-(N-karboksamido)-karboksamideja
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
DK0687257T3 (da) 4-amino-2-(hetero)aryl-butanamider anvendelige som 5HT1A-antagonister